Article Text

Download PDFPDF
Role of immunotherapy in oligometastatic nonsmall cell lung cancer
  1. Yehuda Galili1,
  2. Ahmad El-Far2,
  3. Jennifer Tseng1 and
  4. Steve Carlan3
  1. 1Department of Medicine, Division of Hematology and Oncology, Orlando Health Corp, Orlando, Florida, USA
  2. 2Division of Hematology and Oncology, UF Health Cancer Center-Orlando Health, Orlando, Florida, USA
  3. 3Department of Obstetrics and Gynecology, Orlando Health Corp, Orlando, Florida, USA
  1. Correspondence to Dr Steve Carlan; stevecarlan{at}gmail.com

Abstract

The approach to metastatic lung cancer has long been focused on palliation therapy and comfort care. Recently, significant subsets of patients who suffer from a limited form of the disease have shown curative outcomes. The oligometastatic disease theory was first introduced in 1995, and since has been applied to many solid tumours. In oligometastatic nonsmall cell lung cancer, current treatment strategies include surgery, radiation therapy and chemotherapy. There is evidence of astounding survival benefits in selected patients treated with immune checkpoint inhibitors. We present three cases with oligometastatic nonsmall cell lung cancer treated with pembrolizumab, an immune checkpoint inhibitor, and describe the outcomes. Immunotherapy with pembrolizumab appears to be an effective adjunctive treatment with low toxicity in oligometastatic nonsmall cell lung cancer.

  • cancer intervention
  • malignant disease and immunosuppression
  • neuroimaging
  • radiotherapy
  • respiratory cancer

Statistics from Altmetric.com

Footnotes

  • Contributors Study Design (A) Data Collection (B) Statistical Analysis (C) Data Interpretation(D) Manuscript Preparation (E) Literature Search (F) Funds Collection (G) YG (A,B,E,F)AE-F (B,F)JT(A,D,E)SC (E,F)

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.